Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 16/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505947 | 0.88 | MRGPRX4 (0.55) | MRGPRX4ALDH1A1GAAL3MBTL1MAOB | |
| SCHEMBL4507699 | 0.86 | MRGPRX4 (0.83) | MRGPRX4 | |
| SCHEMBL4492301 | 0.86 | MRGPRX4 (0.50) | MRGPRX4ALDH1A1GAANPC1MAPT | |
| SCHEMBL4517687 | 0.83 | MAPT (0.63) | MRGPRX4ALDH1A1L3MBTL1NPC1MAPT | |
| SCHEMBL4504246 | 0.80 | MRGPRX4 (0.56) | MRGPRX4ALDH1A1L3MBTL1NPC1MAPT | |
| SCHEMBL4499573 | 0.80 | MRGPRX4 (0.53) | MRGPRX4ALDH1A1GAAL3MBTL1NPC1 | |
| SCHEMBL29537205 | 0.78 | GAA (0.59) | ALDH1A1GAAL3MBTL1MAOBMAPT | |
| SCHEMBL20944365 | 0.78 | GAA (0.59) | ALDH1A1GAAL3MBTL1MAOBMAPT | |
| SCHEMBL22480779 | 0.77 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL31568429 | 0.77 | MRGPRX4 (0.64) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | MRGPRX4 1550/4885ALDH1A1 1311/4885GAA 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.